Fig. 3: In vivo inhibition of thrombin.
From: Development of supramolecular anticoagulants with on-demand reversibility
a, Time course of fibrin fluorescence intensity and total thrombus volume (left) and bar chart quantification of average fibrin intensity and average thrombus volume (right) for control animals (n = 7), argatroban-treated animals (n = 4; 2 mg per kg (body weight) bolus followed by an infusion of 12 mg per kg (body weight)) and A1–E1-treated animals (n = 5; 5 mg per kg (body weight) bolus). Statistical significance between multiple treatment groups was analyzed using an ordinary one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons testing with a single pooled variance. For multiple comparisons testing, the mean of each column was compared to the mean of every other column. Data are presented as mean ± s.e.m., where ‘n’ equals the number of independent experiments performed; NS, not significant (P = 0.6660 for average fibrin intensity and P = 0.5128 for average thrombus volume); **P = 0.0025; ****P < 0.0001; AU, arbitrary units. b, Exemplar image of a thrombus 15 min after needle injury without inhibitor (left), with A1–E1 (center) and with argatroban (right). Platelets are shown in red, fibrin is shown in green, and collagen in the background is shown in white; scale bars, 10 μm.
